These findings presented here expand the current understanding of SGLT2 inhibitors in the management of hypomagnesemia, while laying the foundation to pursue larger clinical investigation to establish a role for SGLT2 inhibition in the treatment of hypomagnesemia. Here, SLC5A2 is linked to Hypomagnesemia.